Qualified veterinarian with 17 years’ of director experience with market leading animal health company, Elanco;
Contributed to the development of animal health products for Elanco globally;
Has gained approval for over 20 drugs in over 100 countries;
Lead global teams across Australia, USA, Europe, Asia and Latin America.
Jeffrey Sherman
Lead Toxicology
Board certified senior Toxicologist with in depth knowledge of VICH GLP and GCP
Diplomat of the American Board of Toxicology with extensive experience in risk assessment, FDA regulations and veterinary medicines
Local, state, federal and international jurisdiction legislative experience
Kevin Willard
Senior Formulations Chemist
Expertise in formulation development, processing (clinical trial manufacture and technical transfer) and GMP Quality;
Specialised in CMC (Chemistry, Manufacturing and Controls) technical writing;
34 years of experience working with market leading Elanco Animal Health and Eli Lilly
Invest in CannPal
CannPal Animal Therapeutics Limited (“CannPal”) is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals. The company is listed on the Australian Stock Exchange (ASX) in 2017, trading under the ASX ticker “CP1”. CannPal was founded to research, develop and commercialise, regulatory approved medicines derived from the medical cannabis plant to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
